Jaguar files for $70M animal health IPO; Vaccinogen garners $80M commitment for cancer vaccine study;

@FierceBiotech: What's the #1 biotech hub for VCs? (It's still not Boston). Report | Follow @FierceBiotech

@JohnCFierce: So now we have multiple stories that Novo isn't interested in big deals. It's not a surprise. More from the WSJ | Follow @JohnCFierce

@EmilyMFierce: Thymus gland grown from reprogrammed cells in lab. FierceBiotech Research story | Follow @EmilyMFierce

> San Francisco-based Jaguar Animal Health has filed for a $70 million IPO. The biotech is working on new therapies for companion and commercial animals, with a lead drug in the clinic for watery diarrhea in dogs. The company says it is planning a rolling new animal drug application, or NADA, for Canalevia for chemotherapy-induced diarrhea, or CID, in dogs, by the end of 2014. S-1

> Frederick, MD-based Vaccinogen has raised $10 million to back its work on a cancer vaccine. A Stockholm-based investor group known as The Investment Syndicate put up the cash, and the biotech has a promise of $70 million more in four payments. Vaccinogen is prepping a confirmatory Phase IIIb pivotal study of the patient-specific vaccine in patients with resectable, Stage 2 colon cancer. Release

Medical Device News

@FierceMedDev: ICYMI yesterday: Researchers develop implant/app combo to monitor glaucoma in aging eyes. Story | Follow @FierceMedDev

@VarunSaxena2: ICYMI: Boston Sci gets bad news on four of 23,000+ vaginal mesh lawsuits. Article | Follow @VarunSaxena2

@EmilyWFierce: Hot on the M&A trail, Medtronic acquires NGC Medical to expand its hospital-services offerings. More from the WSJ | Follow @EmilyWFierce

> Study finds robotic prostate removal surgery results in faster recovery times. Article 

> Xprize seeks Star Trek's tricorder in $10M mobile diagnostics competition. More

> Mobile medical app provider reels in $25M to expand innovative monitoring system. Story

Drug Delivery News

> Fresenius Kabi receives FDA approval of three-chamber bag for parenteral nutrition. Article

> Organic nanoparticles offer 'complete package' against cancer: delivery and imaging. Story

> Vascular device drug delivery company surpasses VC goal. More

> Louisiana Tech researchers use 3-D printing to create bioresorbable drug delivery system. Report

> PharmaJet secures FDA approval for jet injection system for flu vaccine. Article

Diagnostics News

> Flagship Biosciences and Sarepta will automate muscular dystrophy biomarker detection. Story

> FDA signs off on highly specific Type 1 diabetes biomarker test. Report

> Roche's Ventana expands infrastructure in Arizona. More

> UCLA, Harvard and others identify possible TB biomarker. Story

> Illumina, AstraZeneca, Janssen and Sanofi to pursue universal companion Dx test. Article

Pharma Marketing News

> Who's doing the mobile app dance right? Only a few in pharma, report says. Story

> Big Pharma, Big Biotech prepare for showdown in next-gen psoriasis market. Report

> Bristol-Myers gets the approval Gilead didn't want: Daklinza + Sovaldi for hep C. News

> PhRMA jumps into Integrilin off-label case, free-speech arguments at the ready. Article

> Listen to celebrity drug ads? Patients do hear, but they don't obey. More

Suggested Articles

In this week's EuroBiotech Report, Sitryx inks Lilly deal, Genfit downplays COVID-19 impact on NASH data and Gilead tests remdesivir in U.K.

Amgen and new partner Adaptive Biotechnologies are the latest pharma-biotech duo joining forces against the pandemic.

In our EuroBiotech roundup this week, AM-Pharma raises €23 million, Nordic Nanovector makes cuts and Neurimmune, Ethris plan COVID-19 trial.